| Literature DB >> 26750251 |
Michael L Schulte1, Alexandra B Khodadadi2, Madison L Cuthbertson3, Jarrod A Smith4, H Charles Manning5.
Abstract
Herein, we report the discovery of 2-amino-4-bis(aryloxybenzyl)aminobutanoic acids as novel inhibitors of ASCT2(SLC1A5)-mediated glutamine accumulation in mammalian cells. Focused library development led to two novel ASCT2 inhibitors that exhibit significantly improved potency compared with prior art in C6 (rat) and HEK293 (human) cells. The potency of leads reported here represents a 40-fold improvement over our most potent, previously reported inhibitor and represents, to our knowledge, the most potent pharmacological inhibitors of ASCT2-mediated glutamine accumulation in live cells. These and other compounds in this novel series exhibit tractable chemical properties for further development as potential therapeutic leads.Entities:
Keywords: ASCT2; Cancer; Glutamine; Metabolism; SLC1A5
Mesh:
Substances:
Year: 2015 PMID: 26750251 PMCID: PMC4727990 DOI: 10.1016/j.bmcl.2015.12.031
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823